Exercise News and Research

Latest Exercise News and Research

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

Qigong and Tai Chi offer physical and mental health benefits

An across-the-board review of the health effects of Qigong and Tai Chi finds these practices offer many physical and mental health advantages with benefits for the heart, immune system and overall quality of life.

30 Jun 2010

Minnesota professor receives NIH grant to study effectiveness of community-based program to prevent childhood obesity

Many children in the U.S. have poor diets and in fact, 1 in 3 is overweight or obese. Parents struggle to have meals together with children and provide them with nutritious foods. They often rely on convenient and processed foods.

30 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

U.S. Supreme Court declines to hear appeals in civil racketeering lawsuit against cigarette manufacturers

The U.S. Supreme Court today declined to hear appeals in the federal government's civil racketeering lawsuit against cigarette manufacturers. Today's decision upholds the trial court's historic verdict that the cigarette manufacturers are racketeers and have engaged in a decades-long conspiracy to deceive the American public and target children with their deadly and addictive products. That verdict is now final and undeniable: The cigarette manufacturers have been found guilty of engaging in a deadly fraud that is unprecedented in our nation's history.

29 Jun 2010

A natural approach to combat stress

For anyone who knows the racing, "misfiring" brain associated with today's multitasking lifestyles, finding a safe, effective remedy to achieve calm can be a challenge. Women-run Rainbow Light® Nutritional Systems, a leader in natural nutrition for nearly 30 years, has developed a breakthrough remedy to calm the "busy brain" that can impair mental clarity and cause restless sleep.

29 Jun 2010

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Men who use statins to lower their cholesterol are 30 percent less likely to see their prostate cancer come back after surgery compared to men who do not use the drugs, according to researchers at Duke University Medical Center. Researchers also found that higher doses of the drugs were associated with lower risk of recurrence.

29 Jun 2010

Family members who undergo gastric bypass surgery together experience better clinical outcomes

If you and a family member have gastric bypass together, chances are you'll both do much better than if you have surgery alone, according to a new study presented today at the 27th Annual Meeting of the American Society for Metabolic & Bariatric Surgery.

29 Jun 2010

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Results of a new study demonstrated that initial combination therapy with Welchol® (colesevelam HCl) 3.75 g/d and metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter) significantly improved glycemic and lipid control in drug-naive adult type 2 diabetes patients with high LDL cholesterol (LDL-C).

29 Jun 2010

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Astellas Pharma Inc. announced that the company presented results from a Japanese Phase 2 study conducted with ASP1941, a selective SGLT2 inhibitor, at the 70th Scientific Sessions of the American Diabetes Association (ADA) on June 26, 2010 (EST). ASP1941 is designed to block the re-absorption of glucose in the kidney and excrete glucose in the urine.

29 Jun 2010

Older adults spend more time watching TV, but find it less enjoyable

We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.

29 Jun 2010

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the American Diabetes Association's 70th Scientific Sessions.

29 Jun 2010

New equation offers accurate estimation of peak heart rate for women

Women who measure their peak heart rates for exercise will need to do some new math as will physicians giving stress tests to patients.

29 Jun 2010

Bicycling and brisk walking associated with less weight gain in obese, premenopausal women

Bicycling and brisk walking are associated with less weight gain among pre-menopausal women, especially those who are overweight and obese, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Additionally, the report finds that slower walking does not appear to offer the same benefits as brisk walking.

29 Jun 2010

G8 nations commit $5B for maternal, child health; Additional $2.3B committed from other countries, foundations

G8 nations, plus other countries and private organizations, have committed at total of $7.3 billion to improve maternal and child health in the developing world, Canadian Prime Minister Stephen Harper said on Friday at the group's summit in Canada's Muskoka region, All Headline News reports (6/26).

29 Jun 2010

'Beeglue' may help deliver new treatments for fatal infections

Bees could have a key role to play in urgently-needed new treatments to fight the virulent MRSA bug, according to research led at the University of Strathclyde in Glasgow, Scotland.

29 Jun 2010

Athletes live longer: Study

The study featuring in the July 2010 issue of The Journal of Science and Medicine in Sport (JSAMS), published by Sports Medicine Australia, examined the mortality and longevity of elite athletes to understand the association between exercise training and survival rates.

28 Jun 2010

Rexahn announces $10 million registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced it has received commitments from certain institutional investors to purchase an aggregate of $10 million of Rexahn's securities in a registered direct offering.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Exercise News and Research

Latest Exercise News and Research

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Qigong and Tai Chi offer physical and mental health benefits

Minnesota professor receives NIH grant to study effectiveness of community-based program to prevent childhood obesity

BBD reports analyze effectiveness and safety of statin use

U.S. Supreme Court declines to hear appeals in civil racketeering lawsuit against cigarette manufacturers

A natural approach to combat stress

Study: Statins can reduce risk of prostate cancer recurrence after surgery

Family members who undergo gastric bypass surgery together experience better clinical outcomes

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Astellas presents ASP1941 selective SGLT2 inhibitor Phase 2 study results at 70th ADA

Older adults spend more time watching TV, but find it less enjoyable

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

New equation offers accurate estimation of peak heart rate for women

Bicycling and brisk walking associated with less weight gain in obese, premenopausal women

G8 nations commit $5B for maternal, child health; Additional $2.3B committed from other countries, foundations

'Beeglue' may help deliver new treatments for fatal infections

Athletes live longer: Study

Rexahn announces $10 million registered direct offering

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Linagliptin mono- and combination therapy improves blood glucose control

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Exercise News and Research

Latest Exercise News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in